{"id":"https://openalex.org/W2243473585","doi":"https://doi.org/10.1200/jco.2007.25.18_suppl.14092","title":"A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors","display_name":"A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors","publication_year":2007,"publication_date":"2007-06-20","ids":{"openalex":"https://openalex.org/W2243473585","doi":"https://doi.org/10.1200/jco.2007.25.18_suppl.14092","mag":"2243473585"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2007.25.18_suppl.14092","doi":"https://doi.org/10.1200/jco.2007.25.18_suppl.14092","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2007.25.18_suppl.14092","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108511133","display_name":"William Kevin Kelly","orcid":"https://orcid.org/0000-0003-2629-672X","observed_orcids":["https://orcid.org/0000-0003-2629-672X"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"W. K. Kelly","raw_affiliation_strings":["Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068368047","display_name":"Timothy Anthony Yap","orcid":"https://orcid.org/0000-0002-2154-3309","observed_orcids":["https://orcid.org/0000-0002-2154-3309"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"T. Yap","raw_affiliation_strings":["Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":null,"display_name":"J. Lee","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"J. Lee","raw_affiliation_strings":["Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077199450","display_name":"Ulrik Lassen","orcid":"https://orcid.org/0000-0002-3865-4574","observed_orcids":["https://orcid.org/0000-0002-3865-4574"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"U. Lassen","raw_affiliation_strings":["Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050812177","display_name":"Elizabeth M. Crowley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"E. Crowley","raw_affiliation_strings":["Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047270834","display_name":"Anne Clarke","orcid":"https://orcid.org/0000-0001-5180-8542","observed_orcids":["https://orcid.org/0000-0001-5180-8542"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"A. Clarke","raw_affiliation_strings":["Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109156759","display_name":"Thomas R. Hawthorne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"T. Hawthorne","raw_affiliation_strings":["Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I4210121186"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064336901","display_name":"Peter Buhl-Jensen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"P. Buhl-Jensen","raw_affiliation_strings":["Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I4210121186"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5072378199","display_name":"Johann Sebastian De Bono","orcid":"https://orcid.org/0000-0002-2034-595X","observed_orcids":["https://orcid.org/0000-0002-2034-595X"]},"institutions":[{"id":"https://openalex.org/I2802730090","display_name":"Yale Cancer Center","ror":"https://ror.org/03j7sze86","country_code":"US","type":"facility","lineage":["https://openalex.org/I2802730090","https://openalex.org/I4210117499","https://openalex.org/I4210165192"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"J. de Bono","raw_affiliation_strings":["Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale Cancer Ctr, New Haven, CT; The Royal Marsden NHS Trust, Surrey, United Kingdom; Onkologisk Klinik, Kobenhaven, Denmark; CuraGen Corporation, Branford, CT; Topo Target, Fruebjergvej, Denmark","institution_ids":["https://openalex.org/I2802730090","https://openalex.org/I4210121186"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":15,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"25","issue":"18_suppl","first_page":"14092","last_page":"14092"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/belinostat","display_name":"belinostat","score":0.9879999756813049},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.871999979019165},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.5260000228881836},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9629999995231628},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8809999823570251},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9160000085830688},{"id":"https://openalex.org/keywords/qtc-prolongation","display_name":"QTc prolongation","score":0.7900000214576721},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.5059999823570251},{"id":"https://openalex.org/keywords/refractory-cancer","display_name":"refractory cancer","score":0.6190000176429749},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.5},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.5770000219345093},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.4300000071525574},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.4410000145435333}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9354418516159058},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7582042217254639},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7345120906829834},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.6699679493904114},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.572828471660614},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.5541601777076721},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.5495213866233826},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5386345982551575},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5294857621192932},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.5108213424682617},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4201757311820984},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.39004603028297424},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3433862328529358}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2007.25.18_suppl.14092","doi":"https://doi.org/10.1200/jco.2007.25.18_suppl.14092","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2007.25.18_suppl.14092","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2283143950","https://openalex.org/W2243735979","https://openalex.org/W2265284037","https://openalex.org/W2556560476","https://openalex.org/W2087400050","https://openalex.org/W2142629029","https://openalex.org/W1991376723","https://openalex.org/W2346100223","https://openalex.org/W2979967248","https://openalex.org/W2562853903"],"abstract_inverted_index":{"14092":[0],"Background:":[1],"Belinostat":[2],"(PXD101)":[3],"is":[4,31,197],"a":[5,345],"hydroxamate":[6],"HDAC":[7],"inhibitor":[8],"which":[9,102],"demonstrates":[10],"broad":[11],"anti-neoplastic":[12],"activity":[13,367],"in":[14,17,23,80,115,172,329],"vitro":[15],"and":[16,72,77,122,153,185,218,237,284,291,310,340,368,376],"vivo.":[18],"In":[19,246,298],"Phase":[20,57],"I":[21,58],"studies":[22,127],"patients":[24,132],"(pts)":[25],"with":[26,82,92,134,148],"advanced":[27,83,93],"cancer,":[28],"IV":[29],"belinostat":[30,46,62,109,334],"well-tolerated":[32],"up":[33],"to":[34,97,137,204,349,359],"1000":[35],"mg/m2":[36],"daily":[37,74,114],"x5.":[38],"Preliminary":[39],"results":[40],"of":[41,45,60,70,89,159,193,195,233,337],"an":[42],"oral":[43,50,61],"formulation":[44],"showed":[47],"that":[48],"the":[49,65,157,249,321,363],"bioavailability":[51],"was":[52,296],"20":[53],"-":[54],"50%.":[55],"This":[56],"trial":[59],"will":[63,371],"determine":[64],"maximal":[66],"tolerated":[67],"dose":[68,174,252,361,378],"(MTD)":[69],"once":[71,111],"twice":[73,113],"dosing,":[75],"tolerability":[76],"pharmacokinetics":[78],"(PK)":[79],"pts":[81,91,168,202,247],"solid":[84,94],"tumors.":[85],"Methods:":[86],"Sequential":[87],"cohorts":[88],"3\u20136":[90],"tumors":[95],"refractory":[96],"standard":[98,104],"therapy":[99,105,196],"or":[100,112,229],"for":[101,211],"no":[103,256,305,311],"exists":[106],"were":[107,128,146,213,224,241,255,265,289,304],"administered":[108],"250\u2013500mg":[110],"4":[116],"week":[117],"cycles.":[118],"Fasting":[119],"(day":[120,124],"1)":[121],"non-fasting":[123],"7)":[125],"pharmacokinetic":[126,369],"performed":[129],"on":[130,142,344,374],"all":[131],"along":[133],"serial":[135],"ECGs":[136],"evaluate":[138],"any":[139],"potential":[140],"effects":[141],"QTc":[143],"prolongation.":[144],"Patients":[145],"evaluated":[147],"routine":[149],"blood":[150],"work":[151],"weekly":[152],"tumor":[154],"imaging":[155],"at":[156,176,226,243,335],"end":[158],"cycle":[160],"1":[161,198],"then":[162],"every":[163],"other":[164],"cycle.":[165],"Results:":[166],"Sixteen":[167],"have":[169],"been":[170,327],"treated":[171],"3":[173,235,239,251,263],"levels":[175],"250mg":[177,186,227,230,338,341],"QD":[178,182,228,339],"(6":[179,183],"pts),":[180,268],"500mg":[181,244],"pts)":[184,217],"BID":[187,342],"(4":[188],"pts).":[189,221],"The":[190,207],"median":[191],"number":[192],"cycles":[194],"(range":[199],"1\u20135),":[200],"nine":[201],"continue":[203],"be":[205,350,372],"treated.":[206],"most":[208],"common":[209],"reasons":[210],"discontinuation":[212],"adverse":[214],"event":[215],"(3":[216,220],"PD":[219],"No":[222],"DLTs":[223,232],"identified":[225],"BID.":[231],"grade":[234,238,257],"dehydration":[236],"fatigue":[240,266],"reported":[242],"QD.":[245],"from":[248],"first":[250],"cohorts,":[253],"there":[254,303],"4/5":[258],"events":[259],"reported.":[260],"Other":[261],"Grade":[262],"toxicities":[264],"(2":[267],"abdominal":[269],"pain":[270],"(1":[271,274,278,282,286],"pt),":[272,275,279],"ataxia":[273],"prolonged":[276,280],"INR":[277],"PTT":[281],"pt)":[283],"confusion":[285],"pt).":[287],"Symptoms":[288],"transient":[290],"usually":[292],"resolved":[293],"after":[294],"drug":[295],"held.":[297],">":[299,307,314],"500":[300,308],"ECG\u2019s":[301],"collected,":[302],"QTcF":[306,312],"ms,":[309],"increase":[313],"60":[315],"ms":[316],"above":[317],"baseline.":[318],"To":[319],"date,":[320],"best":[322],"clinical":[323],"response":[324],"observed":[325],"has":[326],"SD":[328],"7":[330],"patients.":[331],"Conclusions:":[332],"Oral":[333],"doses":[336],"given":[343],"continuous":[346],"schedule":[347],"appears":[348],"well":[351],"tolerated.":[352],"Alternative":[353],"dosing":[354],"schedules":[355],"are":[356],"being":[357],"explored":[358],"further":[360],"escalate":[362],"belinostat.":[364],"Updated":[365],"safety,":[366],"data":[370],"presented":[373],"these":[375],"alternate":[377],"schedules.":[379],"[Table:":[380],"see":[381],"text]":[382]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":2}],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2016-06-24T00:00:00"}